Issues
-
Cover Image
Cover Image
Tumor stroma with an abundance of extracellular matrix (ECM) is characteristic of pancreatic cancer. The cover depicts collagen birefringence from polarized light microscopy of a picrosirius red-stained section of a human pancreatic tumor. Type I collagen appear as yellow-red fibers while Type III collagen fibers appear green. In this issue, Honselmann and colleagues identified the BET family of chromatin adaptor proteins as key regulators of the ECM transcriptional program. Further, the authors demonstrated that pharmacological inhibition of these epigenetic regulators alters the structure of collagen fibers in aggressive tumors to a structure more similar to that observed in tumors from patients with better survival. See the article on page 1889 for more information. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Rapid Impact
Dephosphorylation of the Proneural Transcription Factor ASCL1 Re-Engages a Latent Post-Mitotic Differentiation Program in Neuroblastoma
Cancer Genes and Networks
Destrin Contributes to Lung Adenocarcinoma Progression by Activating Wnt/β-Catenin Signaling Pathway
Cancer “-omics”
Cell Fate Decisions
β2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1
Metabolism
Secreted Factors from Adipose Tissue Reprogram Tumor Lipid Metabolism and Induce Motility by Modulating PPARα/ANGPTL4 and FAK
Signal Transduction and Functional Imaging
Tumor Microenvironment and Immunobiology
Neoplastic–Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.